Biological variation of cardiac markers in patients with aortic valve stenosis

Frederique E C M Peeters, Bas L J H Kietseelaer, Judith Hilderink, Noreen van der Linden, Marijke Niens, Harry J G M Crijns, Steven J R Meex

ABSTRACT

Objective Cardiac biomarkers hold promise for follow-up and management of aortic valve stenosis (AVS). When interpreting serial biomarker measurements of patients with AVS, it can be challenging to distinguish ‘real changes’ from ‘random fluctuation’. Hence, robust estimation of the biological variation of these biomarkers is essential. In the present study we assessed biological variation of B-type natriuretic peptide (BNP), N-terminus pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin-T and high-sensitivity troponin-I (hs-TnT and hs-Tnl), and ST2 in subjects with stable AVS.

Methods Serial blood sampling was performed in 25 subjects with moderate AVS—confirmed by echocardiography—and all free from acute cardiovascular events in the past 6 months. Blood samples were taken on seven standardised occasions during 1 year. Analytical variation (CVa), within-subject biological variation (CVI), between-subject biological variation (CVG), index of individuality (II) and reference change values were calculated for all cardiac biomarkers.

Results CVa was highest for BNP (62.0%, 95% CI 52.5 to 75.4) and lowest for hs-Tnl (9.2%, 95% CI 2.8 to 13.8). CVI exceeded the CVa for all biomarkers except BNP, and ranged from 19.8% (95% CI 13.8 to 33.4) for ST2 to 57.2% (95% CI 40.4 to 97.3) for hs-Tnl. NT-proBNP, hs-TnT and ST2 revealed CVI <5%, while BNP and hs-Tnl showed a higher CVI (19.7 and 14.9, respectively). All biomarkers except BNP showed marked individuality, with II ranging from 0.21 to 0.67 (BNP 1.34).

Conclusion This study provides the first biological variation estimates of cardiac biomarkers in patients with stable AVS. These estimates allow a more evidence-based interpretation of biomarker changes in the follow-up and management of patients with AVS.

Trial registration number NCT02510482

INTRODUCTION

Circulating biomarkers are commonly used in clinical decision making for diagnosing, risk stratification and management of various cardiovascular diseases. However, the use of biomarkers in the management of aortic valve stenosis (AVS), the most common type of valvular disease requiring intervention in the Western world, is a topic of debate. The 2017 European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines recommend to incorporate repeated measurements of B-type natriuretic peptide (BNP) in asymptomatic severe AVS. The 2014 American Heart Association/American College of Cardiology (AHA/ACC) guidelines do not recommend biomarkers.

Once present, AVS is a progressive disease with poor understanding of the exact underlying mechanisms. Currently, echocardiography is the gold standard for diagnosis and evaluation; however, progression rates are highly variable and unpredictable. Cardiac biomarkers may have prognostic value in patients with AVS; therefore, measurement of cardiac biomarkers holds potential to be integrated in the follow-up and management of AVS.

What does this study add?

Insight into the naturally occurring fluctuations (biological variation) of biomarkers in stable patients is essential for correct interpretation of serial measurements of biomarkers and discriminate between ‘true changes’ and random fluctuation.

Therefore, we performed serial blood sampling and measured several cardiac biomarkers in subjects with stable AVS and calculated biological variation indices.

These indices approximated those of healthy subjects.

How might this impact on clinical practice?

Our results suggest that absolute changes of biomarkers should be placed in the perspective of patient-specific ranges to identify a patient’s risk, instead of the general population-based thresholds applied in current practice.
combined biomarkers are suggested to be of prognostic value in patients with AVS. Biomarkers hold potential to provide insight into AVS progression and guide timing of intervention. In particular, serial measurements of biomarkers showing changes over time in parallel with AVS progression are of potential use in tailored AVS management. However, to interpret whether changes over time are ‘real’ and not just a physiological fluctuation, knowledge on the magnitude of physiological variation of a biomarker in stable patients is essential. This concept is known as biological variation. Biological variation data, when combined with analytical variation properties of an assay, can be used to calculate reference change values. That is the required threshold for a change between consecutive measurements to be statistically significant, and hence reflect a ‘true change’. Studies investigating biological variation of cardiac biomarkers have been performed in healthy subjects, but data obtained from specific patient populations are rare, limiting the generalisability of the findings from healthy subjects to patients. Biological variation of biomarkers in patients with AVS has never been reported.

The aim of the current study was to assess the analytical and biological variation of cardiac biomarkers BNP, N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin-T (hs-TnT), high-sensitivity troponin-I (hs-TnI) and ST2 in patients with stable AVS.

Methods

Study population

This study was executed according to the critical appraisal checklist criteria for biological variation studies by Bartlett et al. The study population consisted of 25 subjects (>18 years) with known moderate AVS who were followed up at the outpatient clinics of the Department of Cardiology in Maastricht University Medical Center+, the Netherlands. Severity of AVS was defined by echocardiographic measurements (mean gradient 20–40 mm Hg, Aortic Valve Area (AVA) 1.0–1.5 cm² or maximal transvalvular velocity 3–3.9 m/s). Prior to inclusion, subjects were clinically stable and without complaints directly related to AVS. Exclusion criteria were presence of severe AVS, left ventricular ejection fraction (LVEF) <50%, documented atrial fibrillation in the last year, chronic kidney disease (glomerular filtration rate <45 mL/min/1.73 m²), and a history of acute myocardial infarction, hospitalisation for heart failure or a pulmonary embolism within 6 months prior to inclusion. Subjects who met any of the exclusion criteria and those unable to provide written informed consent were not included. At the end of the study period, subjects were evaluated to monitor progression of AVS and indication for surgical intervention. Subjects with symptomatic AVS and those showing an increase in mean gradient >7 mm Hg or maximum velocity >0.3 m/s were reported as progressive. This study was performed according to the Declaration of Helsinki and was approved by the local Institutional Review Board. All study subjects provided written informed consent. This study was registered at www.clinicaltrials.gov.

Study design

All subjects visited the outpatient clinics of cardiology of our centre on seven occasions during 1 year (baseline and 1 day, 1 week, 1 month, 3 months, 6 months and 12 months). Visits and blood samplings were performed in a standardised manner, and all patients were asked to refrain from intense physical labour and exercise training 2 days before each visit. All patient visits took place between 08:00 and 09:00, during which standard history taking and a standardised questionnaire (including medication use) were performed. Blood sampling was performed through standard venipuncture in seated position.

Laboratory measurements

Blood samples were collected in serum and EDTA tubes. Immediately after collection, standard haematological parameters (haemoglobin, haematocrit, white cell counts, neutrophils) were measured in EDTA samples using the Sysmex XE-5000 analyser (Sysmex, Kobe, Japan). The serum samples were allowed to clot and were centrifuged after 25 min (12 min, 2950g). Directly after aliquoting, samples were stored at −80°C until further analyses (performed in one batch).

NT-proBNP and hs-TnI levels were measured on the cobas 6000 analyser. hs-TnI was measured with the STAT high-sensitivity troponin-I assay (Architect 2000, Abbott Diagnostics). BNP was measured on the Architect analyser (Abbott Diagnostics) and ST2 using the Presage ST2 Assay (Critical Diagnostics). To estimate analytical variation, 60%–100% of BNP, NT-proBNP, hs-TnI, hs-TnI and ST2 measurements were performed in duplicate.

Echocardiography

Standard two-dimensional transthoracic echocardiography was performed by an independent observer prior to inclusion and during regular visits to the outpatient clinics according to the European Association of Echocardiography guidelines.

Statistical analyses

Cochran’s C test was used to test data for homogeneity in analytical and within-subject biological variances as suggested by Fraser and Harris. Subjects were excluded until homogeneity of variances was achieved. Between-subject outliers were identified using the criteria of Reed. Between-subject biological variation (CVs), within-subject biological variation (CVI) and analytical variation (CVa) were calculated using a balanced analysis of variance with a nested random design in two levels. The method of Burdick and Graybill was used accordingly to calculate 95% CIs of the variance components. Additionally, the index of individuality (II) and reference change value (RCV) were calculated. An II of >1.4 indicates that the parameter shows very little individuality, and therefore the use of population-based reference values is considered appropriate because unusual values

Peeters FECM, et al. Open Heart 2019:6:e001040. doi:10.1136/openhrt-2019-001040
for almost all subjects will be outside the reference limits. However, an II of <0.6 and the use of RCVs may have added value over population-based reference values. RCV is the required threshold for a change between consecutive measurements to be statistically significant.\textsuperscript{13,30} The II and RCV were calculated according to the method described by Petersen et al and Fraser and Harris.\textsuperscript{25,31,32} II was calculated using the following formula: $II = \sqrt{(CV_P^2 + CV_A^2)/CV_A}$. The RCV was calculated using the following formula: $RCV = Z*\sqrt{2*(CV_P^2 + CV_A^2)}$. In this formula, $Z$ represents the number of SD appropriate for the desired level of statistical significance for a bidirectional change. For RCV calculations in this study, a Z-score of 1.96 was used. Additionally, RCVs were calculated and evaluated after log-normal transformation.\textsuperscript{33} All statistical analyses were performed using SPSS Statistics V.22.

**RESULTS**

**Baseline population characteristics**
A total of 25 subjects with moderate AVS participated in the current study. The mean age (±SD) was 66±6 years, and 44% (n=11) of the subjects were female. All subjects had moderate AVS on baseline echocardiography (median (IQR) mean gradient 25 (11) mm Hg, maximum velocity 340 (65) cm/s and aortic valve area 1.3 (0.2) cm$^2$), and the median (IQR) LVEF was 63 (5)%. None had complaints attributable to AVS. The baseline concentrations of all biomarkers are shown in figure 1.

**Biological variation in stable AVS**
Sample collection was complete for all subjects. Figure 1 shows the baseline characteristics of the total population. Biomarker concentration ranges per subject (BNP, NT-proBNP, hs-TnT, hs-TnI and ST2) are plotted in figure 2.

In nine subjects, AVS was progressive (figure 1). Therefore, the primary analysis to determine biological variation was performed in the group of subjects who remained
clinically stable during follow-up (n=16). An overview of outliers and excluded subjects per biomarker is provided in online supplementary table 1. Variation components of all cardiac biomarkers are listed in table 1.

NT-proBNP, hs-TnT, hs-TnI and ST2 revealed lower within-subject (CVw) than between-subject (CVb) values. Hs-TnI demonstrated the lowest and BNP the highest CVw (9.1%, 95% CI 2.8 to 13.8 vs 62.0%, 95% CI 52.5 to 75.4). Except for BNP, CVb was consistently higher than CVw, and ranged from 19.8% (95% CI 13.8 to 33.4) for ST2 to 57.2% (95% CI 40.4 to 97.3) for hs-TnT. Duplicate measurements allowed calculation of CVA: NT-proBNP, hs-TnT and ST2 were measured with a CVA <5%, whereas BNP and hs-TnI showed higher CVA (19.7% and 14.9%, respectively).

Additionally, the variation between specific set points, known as the index of individuality (II), was calculated. All biomarkers except BNP showed marked individuality, with II ranging from 0.2 to 0.7 (BNP 1.3). High individuality of biomarkers (II <0.6) implies that the use of RCVs for monitoring offers substantial benefit over classical population-based reference intervals.

![Figure 2](image2.png) Ranges of biomarker concentration per subject for BNP, NT-proBNP, hs-TnT, hs-TnI and ST2 over seven measurement points during 1 year of follow-up. Parameters are shown in absolute ranges (minimum–maximum concentration). Red lines indicate subjects with progressive aortic valve stenosis. BNP, B-type natriuretic peptide; hs-TnI, high-sensitivity troponin-I; hs-TnT, high-sensitivity troponin-T; NT-proBNP, N-terminus pro-brain natriuretic peptide.
Aortic and vascular disease

Table 1  Analytical variation, biological variation, indexes of individuality and reference change values in stable aortic valve stenosis

| Mean concentration | Variance components | RCV† | II |
|--------------------|---------------------|------|----|
|                    | CV<sub>α</sub>       | CV<sub> β</sub> | CV<sub> α</sub>* | Normal | Log-normal |
| BNP 5.7 pmol/L     | 48.4 (28.6 to 91.7) | 62.0 (52.5 to 75.4) | 19.7 (17.1 to 23.4) | ‡ | 52.6; −34.5 | 1.3 |
| NT-proBNP 9.3 pmol/L | 43.0 (27.7 to 88.8) | 22.0 (18.3 to 27.5) | 1.9 (1.6 to 2.3) | ‡ | 44.6; −30.9 | 0.5 |
| hs-TnT 9.2 ng/L    | 57.2 (40.4 to 97.3) | 11.2 (9.6 to 13.5) | 3.7 (3.2 to 4.3) | ‡ | 43.1; −30.1 | 0.2 |
| hs-TnI 3.6 ng/L    | 35.0 (23.3 to 67.6) | 9.2 (2.8 to 13.8) | 14.9 (12.7 to 18.0) | ‡ | 73.1; −42.2 | 0.5 |
| ST2 28.4 ng/mL     | 19.8 (13.8 to 33.4) | 13.1 (11.3 to 15.6) | 2.0 (1.7 to 2.4) | ‡ | 36.83 | § | 0.7 |

Values are % (95% CI).
†On the basis of a Z-score of 1.96.
§On the basis of duplicate measurements.
‡Non-normal distribution.
Normal distribution.
BNP, brain natriuretic peptide; CV<sub>α</sub>, analytical coefficient of variation; CV<sub>β</sub>, between-person coefficient of variation; CV<sub>α*</sub>, within-person biological coefficient of variation; II, index of individuality; NT-proBNP, N-terminus pro-brain natriuretic peptide; RCV, reference change value; hs-TnI, high-sensitivity troponin-I; hs-TnT, high-sensitivity troponin-T.

Biomarkers in stable and progressive AVS

The subpopulation of subjects showing progressive aortic valve disease (n=9) was explored. Five patients progressed to symptomatic AVS after their 6-month visit. Another four remained asymptomatic, but showed progressive disease during echocardiographic examination after 1 year of follow-up. Since biomarker results from these progressive patients cannot be used to determine biological variation, we explored whether the investigated biomarkers have potential value to discriminate stable from progressive AVS. The annual variation (defined as the difference between initial measurement and measurement after 1 year) was calculated for each biomarker in all progressive subjects. These values were compared with the (log-normal) RCVs found in the stable population (figure 3). Hs-TnT and NT-proBNP variation was higher in one of nine subjects with progressive disease, whereas the RCV of ST2 was surpassed in one of nine subjects. None of the progressive subjects showed variation higher than the RCV for BNP and hs-TnI.

DISCUSSION

The management and follow-up of patients with AVS would benefit from cardiac biomarker changes that reflect or even precede clinical progression of AVS. The interpretation whether an observed biomarker change over time is clinically relevant is challenging. To interpret serial measurements, knowledge about variation components of biomarkers is essential.

This study is the first to examine biological variation of several cardiac biomarkers (BNP, NT-proBNP, hs-TnT, hs-TnI and ST2) in subjects with stable moderate AVS. We report two major findings: First, we found substantial biological variation within and between subjects with AVS (CV<sub>α</sub>=9%–62% and CV<sub>α*</sub>=20%–58%), corresponding with previous studies that were conducted in healthy subjects. Within-subject variability was relatively small for ST2 and hs-TnT and hs-TnI, whereas within-subject variation was high for BNP and NT-proBNP. These results show that observed changes in consecutively measured BNP and NT-proBNP samples must be relatively large to meet the threshold for a ‘true’ change, while smaller changes between serial measurements of hs-TnT and ST2 are indicative of a significant change. Studies examining biological variation have been performed in healthy populations, but a growing interest in variation components of biomarkers in populations with (cardiovascular) disease resulted in newer studies addressing biological variation in heart failure and chronic kidney disease. We found that indices of biological variation in stable AVS approximated indices found in studies investigating biological variation in healthy subjects and chronic and stable heart failure.

Second, between-subject variation was higher than within-subject variation in all biomarkers but BNP in our population. Both affect the II, and therefore we found low indexes of individuality in all biomarkers (except BNP) and thus marked individuality in our population. Therefore, the use of population-based reference values is of limited utility. Instead, the use of RCV is of value in these biomarkers.

From a clinical perspective, a low II underlines the importance of the use of RCV instead of general population-based reference intervals to interpret serial measurements in an individual. However, the individual variation is undervalued in daily practice, as we tend to interpret
Figure 3  Observed variation in 1 year of patients with progressive aortic valve stenosis. Black dots represent the difference between the initial and last measurements (1 year). Green boxes represent (log-normal) reference change values, and dots within these boxes represent random fluctuations. Dots in the red boxes are considered true changes (outside the RCV limits). BNP, B-type natriuretic peptide; hs-TnI, high-sensitivity troponin-I; hs-TnT, high-sensitivity troponin-T; NT-proBNP, N-terminus pro-brain natriuretic peptide; RCV, reference change value.

CONCLUSION

This study provides the first biological variation estimates of BNP, NT-proBNP, hs-TnI, hs-TnT and ST2 in patients with stable AVS. These estimates allow a more evidence-based interpretation of biomarker changes in the follow-up and management of patients with AVS.

Acknowledgements  We thank Abbott Diagnostics for providing kits to measure BNP and troponin-I.

Contributors All authors contributed to the planning, conduct and reporting of the work described. FECMP and SJRM are responsible for the overall content of this manuscript.

Funding This study was supported by a research grant from Stichting De Weijerhorst (Maastricht, the Netherlands) to Professor van Dieijen-Visser. The sponsor had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, or in the preparation, review or approval of the manuscript and the decision to submit the manuscript for publication.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was performed according to the Declaration of Helsinki and was approved by the local institutional review board. All study subjects provided written informed consent.
Aortic and vascular disease

REFERENCES

1. Toutouzas K, Stathogiannis K, Latsios G, et al. Biomarkers in aortic valve stenosis and their clinical significance in transcatheter aortic valve implantation. CMC 2017:24.

2. van Holten TC, Waanders LF, de Groot PG, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One 2013;8:e62060.

3. Staib JL, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017:38:2739–91.

4. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation 2014;129(S):e521–643.

5. Peeters FECM, Meex SJR, Dwweck MR, et al. Calcific aortic valve stenosis: hard disease in the heart: a biomolecular approach towards diagnosis and treatment. Eur Heart J 2018;39:3618–24.

6. Small A, Kiss D, Giri J, et al. Biomarkers of calcific aortic valve disease. Arterioscler Thromb Vasc Biol 2017;37:623–32.

7. Chin CWL, Shah ASV, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. European Heart Journal 2014;35:2312–21.

8. Lindman BR, Breyele JG, Schilling JD, et al. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart 2015;101:1382–8.

9. Dahou A, Clavel M-A, Capoulade R, et al. B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin for Risk Stratification in Low-Flow, Low-Gradient Aortic Stenosis: A Substudy of the TOPAS Study. JACC Cardiovasc Imaging 2017;10:939–47.

10. Dwweck MR, Everett RJ, Multibiomarker strategies in aortic stenosis. JACC Cardiovasc Imaging 2018;11:948–50.

11. Fraser CG. Biological variation: from principles to practice. Washington DC: AACR Press, 2001.

12. Bailey D, Bevilacqua V, Colantonio DA, et al. Pediatric within-day biological variation and quality specifications for 38 biochemical markers in the CALIPER cohort. Clinical Chemistry 2014;60:518–29.

13. Fraser CG. Reference change values. Clin Chem Lab Med 2011;50:807–12.

14. Harris EK. Effects of intra- and interindividual variation on the appropriate use of normal ranges. Clin Chem 1974;20:1353–42.

15. Frankenstein L, Wu AHB, Hallermayer K, et al. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clinical Chemistry 2011;57:1068–71.

16. Klinkenberg LJ, van Dijk J-W, Tan FES, et al. Circulating cardiac troponin T exhibits a diurnal rhythm. J Am Coll Cardiol 2014;63:1789–95.

17. Meijers WC, van der Velde AR, Muller Kobold AC, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. European Journal of Heart Failure 2017;19:357–65.

18. van der Linden N, Hilderink JM, Cornelis T, et al. Twenty-four-hour biological variation profiles of cardiac troponin I in individuals with or without chronic kidney disease. Clinical Chemistry 2017;63:1655–6.

19. Wu AHB, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355–6.

20. Wu AHB, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013;165:995–9.

21. Bartlett WA, Braga F, Carobene A, et al. A checklist for critical appraisal of studies of biological variation. Clinical chemistry and laboratory medicine 2015;53:879–85.

22. Otto CM, Burwash IG, Leggett ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262–70.

23. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611–7.

24. Evangelista A, Flachskampf F, Lancellotti P, et al. European association of echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. European Journal of Echocardiography 2008;9:438–48.

25. Fraser GG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Critical Reviews in Clinical Laboratory Sciences 1989;27:409–37.

26. Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971;17:275–84.

27. Dixon WL. Processing data for outliers. Biometrics 1953;9:74–89.

28. Roraas T, Petersen PH, Sandberg S. Confidence intervals and power calculations for within-person biological variation: effect of analytical imprecision, number of replicates, number of samples, and number of individuals. Clinical Chemistry 2012;58:1306–13.

29. Erdick RK, Graybill RA. Confidence intervals on variance components. New York: Marcel Dekker, 1992.

30. Hilderink JM, Klinkenberg LJ, Aakre KM, et al. Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clinical chemistry and laboratory medicine 2017;55:1013–24.

31. Harris EK, Yasaka T. On the calculation of a “reference change” for comparing two consecutive measurements. Clin Chem 1983;29:25–30.

32. Petersen PH, Fraser CG, Sandberg S, et al. The index of individuality is often a misinterpreted quantity characteristic. Clin Chem Lab Med 1999;37:655–61.

33. Fokkema MReRF et al. Reference change values for brain natriuretic peptides revisited. Clinical Chemistry 2006;52:1602–3.

34. Henri C, Dulgheru R, Magne J, et al. Impact of Serial B-Type Natriuretic Peptide Changes for Predicting Outcome in Asymptomatic Patients With Aortic Stenosis. Canadian Journal of Cardiology 2016;32:183–9.

35. Lancellotti P, Dulgheru R, Magne J, et al. Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis. Plos One 2015;10:e0138940.

36. Rosja H, Andreasen J, Edvardsen T, et al. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. The American Journal of Cardiology 2011;108:88–91.

37. Shen M, Tastet L, Bergler-Klein J, et al. Blood, tissue and imaging biomarkers in calcific aortic valve stenosis: past, present and future. Curr Opin Cardiol 2018;33:125–33.

38. Schindler EI, Szymanski JJ, Hock KG, et al. Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults. Clin Chem 2016;62:360–6.

39. Harris EK. Statistical aspects of reference values in clinical pathology. Prog Clin Pathol 1981;8:45–66.